Nobilon, the human vaccine business of Schering-Plough Corporation (Kenilworth, NJ), have entered into an agreement with the World Health Organization (WHO, Geneva, Switzerland) to provide access to pandemic influenza vaccine manufacturing technology to developing countries.
Nobilon, the human vaccine business of Schering-Plough Corporation (Kenilworth, NJ), have entered into an agreement with the World Health Organization (WHO, Geneva, Switzerland) to provide access to pandemic influenza vaccine manufacturing technology to developing countries.
Under the agreement, Nobilon has granted the WHO a nonexclusive license to develop, register, manufacture, use, and sell seasonal and pandemic live attenuated influenza vaccines (LAIV) produced in embryonated chicken eggs. The WHO will be permitted to grant a sublicense to vaccine manufacturers in developing countries working within the framework of the WHO Global Vaccine Action Plan. Sublicensed vaccine manufacturers will be able to provide vaccines to the public sector of developing countries royalty-free.
Egg-based LAIV technology is specifically considered attractive for this purpose because the manufacturing technology process is easier to transfer, capital investment is lower and yields are higher as compared to inactivated influenza vaccines.
The WHO Global Vaccine Action Plan seeks to expand influenza vaccine manufacturing capacity in developing countries and enhance the global supply for pandemic vaccines.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.